FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma By Ogkologos - January 28, 2026 499 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRANSCEND FL-MZL Cohort Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Durable Activity of Repotrectinib in Patients with ROS1 Fusion–Positive NSCLC Regardless... January 15, 2024 Cancer in My Community: Providing Free Access to Cancer Care in... September 17, 2020 Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced... June 2, 2025 Prognostic Value of Longitudinal ctDNA Assessment in Oesophageal Cancer January 11, 2021 Load more HOT NEWS “My First Thought Was My Children:” Young Mom Diagnosed With Triple-Negative... The Benefits of Yoga During Cancer and How to Get Started FDA Expands Indications for Lutetium Lu 177 Vipivotide Tetraxetan to Include... Reducing Cancer’s Global Burden: A Conversation with NCI’s Dr. Satish Gopal
